Please use this identifier to cite or link to this item:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

AuthorsGoicoechea, Ibai; Puig, Noemi; Cedena, Maria-Teresa; Burgos, Leire; Cordón, Lourdes; Vidriales, Maria Belén; Flores-Montero, Juan; Gutiérrez, Norma Carmen; Calasanz, Mª Jose; Martín-Ramos, María-Luisa; Lara-Astiaso, David; Vilas-Zornoza, Amaia; Alignani, Diego; Rodríguez, Idoia; Sarvide, Sarai; Alameda, Daniel; Garcés, Juan José; Rodríguez, Sara; Fresquet, Vicente; Celay, Jon; García-Sanz, Ramón; Martínez-López, Joaquín; Oriol, Albert; Ríos, Rafael; Martín-Sánchez, Jesús CSIC ORCID; Martínez-Martínez, Rafael; Sarra, Josep; Hernandez, Miguel T.; Rubia, Javier de la; Krsnik, Isabel; Moraleda, José María; Palomera, Luis; Bargay, Joan; Martínez-Climent, José Ángel; Orfao, Alberto CSIC ORCID ; Rosiñol, Laura; Mateos, Maria Victoria; Lahuerta, Juan José; Bladé, Joan; San Miguel, Jesús F. CSIC ORCID; Paiva, Bruno
KeywordsClinical Trials and Observations
Lymphoid Neoplasia
Multiple Myeloma
Issue Date7-Jan-2021
PublisherAmerican Society of Hematology
CitationBlood 137(1): 49-60 (2021)
AbstractPatients with multiple myeloma (MM) carrying standard- or high-risk cytogenetic abnormalities (CAs) achieve similar complete response (CR) rates, but the later have inferior progression-free survival (PFS). This questions the legitimacy of CR as a treatment endpoint and represents a biological conundrum regarding the nature of tumor reservoirs that persist after therapy in high-risk MM. We used next-generation flow (NGF) cytometry to evaluate measurable residual disease (MRD) in MM patients with standard- vs high-risk CAs (n = 300 and 90, respectively) enrolled in the PETHEMA/GEM2012MENOS65 trial, and to identify mechanisms that determine MRD resistance in both patient subgroups (n = 40). The 36-month PFS rates were higher than 90% in patients with standard- or high-risk CAs achieving undetectable MRD. Persistent MRD resulted in a median PFS of ∼3 and 2 years in patients with standard- and high-risk CAs, respectively. Further use of NGF to isolate MRD, followed by whole-exome sequencing of paired diagnostic and MRD tumor cells, revealed greater clonal selection in patients with standard-risk CAs, higher genomic instability with acquisition of new mutations in high-risk MM, and no unifying genetic event driving MRD resistance. Conversely, RNA sequencing of diagnostic and MRD tumor cells uncovered the selection of MRD clones with singular transcriptional programs and reactive oxygen species–mediated MRD resistance in high-risk MM. Our study supports undetectable MRD as a treatment endpoint for patients with MM who have high-risk CAs and proposes characterizing MRD clones to understand and overcome MRD resistance. This trial is registered at as #NCT01916252.
DescriptionPETHEMA/GEM Cooperative Group.
Publisher version (URL)
Identifiersdoi: 10.1182/blood.2020006731
issn: 0006-4971
e-issn: 1528-0020
Appears in Collections:(IBIS) Artículos
(IBMCC) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Page view(s)

checked on Apr 1, 2023


checked on Apr 1, 2023

Google ScholarTM




WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.